Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

Noninvasive prenatal test for fetal chromosomal aneuploidies by massively parallel sequencing of cell-free fetal DNA in maternal plasma: The first clinical experience in Korea

  • Han, Sung-Hee (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Yang, Young-Ho (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Ryu, Jae-Song (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Kang, Myung-Soo (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Kim, Young-Jin (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories) ;
  • Lee, Kyoung-Ryul (Division of Prenatal Molecular Genetics, Department of Laboratory Medicine, Seoul Clinical Laboratories)
  • Received : 2015.10.12
  • Accepted : 2015.11.19
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Noninvasive prenatal test (NIPT) by massively parallel sequencing (MPS) of cell-free fetal DNA in maternal plasma marks a significant advancement in prenatal screening, minimizing the need for invasive testing of fetal chromosomal aneuploidies. Here, we report the initial clinical performance of NIPT in Korean pregnant women. Materials and Methods: MPS-based NIPT was performed on 910 cases; 5 mL blood samples were collected and sequenced in the Shenzhen BGI Genomic Laboratory to identify aneuploidies. The risk of fetal aneuploidy was determined by L-score and t-score, and classified as high or low. The NIPT results were validated by karyotyping for the high-risk cases and neonatal follow-up for low-risk cases. Results: NIPT was mainly requested for two clinical indications: abnormal biochemical serum-screening result (54.3%) and advanced maternal age (31.4%). Among 494 cases with abnormal biochemical serum-screening results, NIPT detected only 9 (1.8%) high-risk cases. Sixteen cases (1.8%) of 910 had a high risk for aneuploidy: 8 for trisomy 21, 2 for trisomy 18, 1 for trisomy 13, and 5 for sex chromosome abnormalities. Amniocentesis was performed for 7 of these cases (43.8%). In the karyotyping and neonatal data, no false positive or negative results were observed in our study. Conclusion: MPS-based NIPT detects fetal chromosomal aneuploidies with high accuracy. Introduction of NIPT as into clinical settings could prevent about 98% of unnecessary invasive diagnostic procedures.

Keywords

References

  1. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11. https://doi.org/10.1056/NEJMoa043693
  2. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009;34:14-8.
  3. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15. https://doi.org/10.1002/pd.2637
  4. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7. https://doi.org/10.1016/S0140-6736(97)02174-0
  5. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401. https://doi.org/10.1136/bmj.c7401
  6. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e1-11. https://doi.org/10.1016/j.ajog.2010.12.060
  7. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9. https://doi.org/10.1016/j.ajog.2012.01.030
  8. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20. https://doi.org/10.1097/GIM.0b013e3182368a0e
  9. Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KC, Leung TY, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 2011;6:e21791. https://doi.org/10.1371/journal.pone.0021791
  10. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901. https://doi.org/10.1097/AOG.0b013e31824fb482
  11. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8. https://doi.org/10.1016/j.ajog.2012.05.021
  12. Guex N, Iseli C, Syngelaki A, Deluen C, Pescia G, Nicolaides KH, et al. A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. Prenat Diagn 2013;33:707-10. https://doi.org/10.1002/pd.4130
  13. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305. https://doi.org/10.1038/gim.2011.73
  14. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened firsttrimester population. Am J Obstet Gynecol 2012;207:374.e1-6. https://doi.org/10.1016/j.ajog.2012.08.033
  15. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370:799-808. https://doi.org/10.1056/NEJMoa1311037
  16. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4. https://doi.org/10.1097/01.AOG.0000423819.85283.f4
  17. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013;22:291-5. https://doi.org/10.1007/s10897-012-9564-0
  18. Benn P, Borrell A, Cuckle H, Dugoff L, Gross S, Johnson JA, et al. Prenatal detection of Down syndrome using massively parallel sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn 2012;32:1-2.
  19. Morgan S, Delbarre A, Ward P. Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol 2013;41:526-9. https://doi.org/10.1002/uog.12384
  20. Muller PR, Cocciolone R, Haan EA, Wilkinson C, Scott H, Sage L, et al. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005. Am J Obstet Gynecol 2007;196:315.e1-7. https://doi.org/10.1016/j.ajog.2007.01.037
  21. Musci TJ, Fairbrother G, Batey A, Bruursema J, Struble C, Song K. Noninvasive prenatal testing with cell-free DNA: US physician attitudes toward implementation in clinical practice. Prenat Diagn 2013;33:424-8. https://doi.org/10.1002/pd.4091
  22. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-6. https://doi.org/10.1002/pd.4125
  23. Dan S, Wang W, Ren J, Li Y, Hu H, Xu Z, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012;32:1225-32. https://doi.org/10.1002/pd.4002
  24. Committee Opinion Summary No. 640: Cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015;126:691-2. https://doi.org/10.1097/01.AOG.0000471171.86798.ac
  25. Morris JK, Alberman E, Scott C, Jacobs P. Is the prevalence of Klinefelter syndrome increasing? Eur J Hum Genet 2008;16:163-70. https://doi.org/10.1038/sj.ejhg.5201956
  26. Lau TK, Chan MK, Salome Lo PS, Chan HY, Chan WK, Koo TY, et al. Non-invasive prenatal screening of fetal sex chromosomal abnormalities: perspective of pregnant women. J Matern Fetal Neonatal Med 2012;25:2616-9. https://doi.org/10.3109/14767058.2012.712569
  27. Jeon KC, Chen LS, Goodson P. Decision to abort after a prenatal diagnosis of sex chromosome abnormality: a systematic review of the literature. Genet Med 2012;14:27-38. https://doi.org/10.1038/gim.0b013e31822e57a7
  28. Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003;(3):CD003252.
  29. Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 2005;193:322-6. https://doi.org/10.1016/j.ajog.2005.02.134
  30. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6. https://doi.org/10.1016/S0140-6736(97)11280-6
  31. Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH. Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study. BMJ 2006;332:452-5. https://doi.org/10.1136/bmj.38730.655197.AE
  32. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372:1589-97. https://doi.org/10.1056/NEJMoa1407349